Stock price performance of Stemline Therapeutics, Inc. is analyzed for various periods using several stock trading signals. The stock price have dropped -46.53% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -11.49% . Looking at the past 52 week period, the stock price is up at 52.68% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Stemline Therapeutics, Inc. has a positive value of 129.61 compared to overall market. For this week, the average consensus of the company shares are rated as a Strong Buy. The stock has recorded a 20-day Moving Average of 13.19% and the 50-Day Moving Average is 16.2%.The 200 Day SMA reached 10.41%
Based on the Stock Research Stemline Therapeutics, Inc. Relative Strength Index signal is in over sold territory with a range of 27.74. Stemline Therapeutics, Inc. (NASDAQ:STML) has tumbled 35.78% during the past week and has dropped 49.23% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 35.86%. Stemline Therapeutics, Inc. (NASDAQ:STML) has underperformed the index by 49.68% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Company has reported several Insider transactions to the SEC, on Jan 24, 2017, David Gionco (Chief Accounting Officer) sold 3,593 shares at 11.46 per share price.On Jan 13, 2017, Kenneth Hoberman (Chief Operating Officer) sold 9,110 shares at 13.82 per share price.On Feb 19, 2016, Ivan Bergstein (Chief Executive Officer) sold 3,244 shares at 4.46 per share price.
Stemline Therapeutics, Inc. (NASDAQ:STML) : On Friday heightened volatility was witnessed in Stemline Therapeutics, Inc. (NASDAQ:STML) which led to swings in the share price. The stock opened for trading at $5.95 and hit $7.25 on the upside , eventually ending the session at $6.55, with a gain of 16.96% or 0.95 points. The heightened volatility saw the trading volume jump to 1,713,855 shares. The 52-week high of the share price is $14.6 and the company has a market cap of $125 million. The 52-week low of the share price is at $3.88 .
Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.